4//SEC Filing
ARSENAULT KAITLYN 4
Accession 0001516551-24-000012
CIK 0001516551other
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 6:42 PM ET
Size
8.4 KB
Accession
0001516551-24-000012
Insider Transaction Report
Form 4
ARSENAULT KAITLYN
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-02-29+75,000→ 75,000 totalExercise: $14.56Exp: 2034-03-01→ Common Stock (75,000 underlying) - Award
Common Stock
2024-02-29+25,000→ 210,738 total
Footnotes (3)
- [F1]Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest at if the Company is acquired for total consideration of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the options will become fully vested.
- [F2]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F3]The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested.
Documents
Issuer
Skye Bioscience, Inc.
CIK 0001516551
Entity typeother
Related Parties
1- filerCIK 0001877242
Filing Metadata
- Form type
- 4
- Filed
- Feb 29, 7:00 PM ET
- Accepted
- Mar 1, 6:42 PM ET
- Size
- 8.4 KB